SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

Brief Summary:
Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue. There are no current targeted therapies to prevent or reverse the chronic inflammation of obesity, and a better understanding of these inflammatory pathways in humans is key to future therapeutic interventions. This project will determine both the anti-inflammatory potential of the SGLT2 inhibitor empagliflozin, and the contribution of adipose inflammation to surrogate measures of cardiovascular disease in a randomized controlled trial of obese patients.

Condition or disease

Obesity Pre-diabetes
Drug: Empagliflozin 25 MG
Phase 1 Phase 2

Detailed Description:
This study will be expanded to include another 10 participants. Enrollment will begin July 1, 2023.

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 21, 2023Comments | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine